Table 3

Linear mixed-effect models of SLE likelihood in relation to testing arm and MAP/CB-CAPs test result (positive or negative).

Slope estimate (SEM)P value
Time from enrolment (per visit follow-up)−0.23±0.03<0.001
Randomisation to MAP/CB-CAPs testing arm−0.174±0.0800.030
Positive MAP/CB-CAPs test results+0.311±0.1160.008
  • CB-CAPs, cell-bound complement activation products; MAP, multianalyte assay panel.